Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
Objectives: Despite concerted efforts, Mycobacterium tuberculosis (M.tb), the pathogen that causes tuberculosis (TB), continues to be a burden on global health, regaining its dubious distinction in 2022 as the world's biggest infectious killer with global COVID-19 deaths steadily declining. The...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223001145 |
| _version_ | 1797813820231516160 |
|---|---|
| author | Sasha E. Larsen Susan L. Baldwin Rhea N. Coler |
| author_facet | Sasha E. Larsen Susan L. Baldwin Rhea N. Coler |
| author_sort | Sasha E. Larsen |
| collection | DOAJ |
| description | Objectives: Despite concerted efforts, Mycobacterium tuberculosis (M.tb), the pathogen that causes tuberculosis (TB), continues to be a burden on global health, regaining its dubious distinction in 2022 as the world's biggest infectious killer with global COVID-19 deaths steadily declining. The complex nature of M.tb, coupled with different pathogenic stages, has highlighted the need for the development of novel immunization approaches to combat this ancient infectious agent. Intensive efforts over the last couple of decades have identified alternative approaches to improve upon traditional vaccines that are based on killed pathogens, live attenuated agents, or subunit recombinant antigens formulated with adjuvants. Massive funding and rapid advances in RNA-based vaccines for immunization have recently transformed the possibility of protecting global populations from viral pathogens, such as SARS-CoV-2. Similar efforts to combat bacterial pathogens such as M.tb have been significantly slower to implement. Methods: In this review, we discuss the application of a novel replicating RNA (repRNA)-based vaccine formulated and delivered in nanostructured lipids. Results: Our preclinical data are the first to report that RNA platforms are a viable system for TB vaccines and should be pursued with high-priority M.tb antigens containing cluster of differentiation (CD4+) and CD8+ T-cell epitopes. Conclusion: This RNA vaccine shows promise for use against intracellular bacteria such as M.tb as demonstrated by the feasibility of construction, enhanced induction of cell-mediated and humoral immune responses, and improved bacterial burden outcomes in in vivo aerosol-challenged preclinical TB models. |
| first_indexed | 2024-03-13T07:57:20Z |
| format | Article |
| id | doaj.art-a98b600396b24f23b2f496a9cb8d00ef |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-03-13T07:57:20Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-a98b600396b24f23b2f496a9cb8d00ef2023-06-02T04:22:43ZengElsevierInternational Journal of Infectious Diseases1201-97122023-05-01130S47S51Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?Sasha E. Larsen0Susan L. Baldwin1Rhea N. Coler2Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, USACenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, USACenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, USA; Department of Global Health, University of Washington, Seattle, USA; Corresponding author.Objectives: Despite concerted efforts, Mycobacterium tuberculosis (M.tb), the pathogen that causes tuberculosis (TB), continues to be a burden on global health, regaining its dubious distinction in 2022 as the world's biggest infectious killer with global COVID-19 deaths steadily declining. The complex nature of M.tb, coupled with different pathogenic stages, has highlighted the need for the development of novel immunization approaches to combat this ancient infectious agent. Intensive efforts over the last couple of decades have identified alternative approaches to improve upon traditional vaccines that are based on killed pathogens, live attenuated agents, or subunit recombinant antigens formulated with adjuvants. Massive funding and rapid advances in RNA-based vaccines for immunization have recently transformed the possibility of protecting global populations from viral pathogens, such as SARS-CoV-2. Similar efforts to combat bacterial pathogens such as M.tb have been significantly slower to implement. Methods: In this review, we discuss the application of a novel replicating RNA (repRNA)-based vaccine formulated and delivered in nanostructured lipids. Results: Our preclinical data are the first to report that RNA platforms are a viable system for TB vaccines and should be pursued with high-priority M.tb antigens containing cluster of differentiation (CD4+) and CD8+ T-cell epitopes. Conclusion: This RNA vaccine shows promise for use against intracellular bacteria such as M.tb as demonstrated by the feasibility of construction, enhanced induction of cell-mediated and humoral immune responses, and improved bacterial burden outcomes in in vivo aerosol-challenged preclinical TB models.http://www.sciencedirect.com/science/article/pii/S1201971223001145RNA vaccineTuberculosisImmunity |
| spellingShingle | Sasha E. Larsen Susan L. Baldwin Rhea N. Coler Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? International Journal of Infectious Diseases RNA vaccine Tuberculosis Immunity |
| title | Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? |
| title_full | Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? |
| title_fullStr | Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? |
| title_full_unstemmed | Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? |
| title_short | Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? |
| title_sort | tuberculosis vaccines update is an rna based vaccine feasible for tuberculosis |
| topic | RNA vaccine Tuberculosis Immunity |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223001145 |
| work_keys_str_mv | AT sashaelarsen tuberculosisvaccinesupdateisanrnabasedvaccinefeasiblefortuberculosis AT susanlbaldwin tuberculosisvaccinesupdateisanrnabasedvaccinefeasiblefortuberculosis AT rheancoler tuberculosisvaccinesupdateisanrnabasedvaccinefeasiblefortuberculosis |